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Abstract
Background: Cytotoxic drugs are non-selective between normal and pathological tissue, and this poses a
challenge regarding the strategy for treatment of tumors. To achieve sufficient antitumor activity for colorectal
carcinoma, optimization of the therapeutic regimen is of great importance. We investigated the ability of
oxaliplatin long-circulating liposomes (PEG-liposomal L-oHP) to provide an improved therapeutic index of colorectal
carcinoma.
Results: We determined that PEG- liposomes conjugated with cells at 2 h, with a mean fluorescence intensity that
was enhanced upon extended induction time. The PEG-liposomal L-oHP induced a significant apoptotic response
as compared with free L-oHP, 23.21% ± 3.38% vs. 16.85% ± 0.98%, respectively. Fluorescence imaging with In-Vivo
Imaging demonstrated that PEG- liposomes specifically targeted tumour tissue. After intravenous injections of PEG-
liposomal L-oHP or free L-oHP, the tumour volume suppression ratio was 26.08% ± 12.43% and 18.19% ± 7.09%,
respectively, the percentage increased life span (ILS%) was 45.36% and 76.19%, respectively, and Bcl-2, Bax mRNA
and protein expression in tumour tissue was 0.27-fold vs. 0.88-fold and 1.32-fold vs. 1.61-fold compared with free
L-oHP, respectively.
Conclusion: The PEG-liposomal L-oHP exhibited a tendency to target tumour tissue and demonstrated a
significantly greater impact on apoptosis compared to free oxaliplatin.
Background
Colorectal carcinoma (CRC) is the third most common
form of cancer in the world, and the rectum exhibits
common internal malignancies [1]. Oxaliplatin (L-oHP)
is a third generation platinum antitumor compound.
Clinically, it is now approved as first-line chemotherapy
in combination with other antitumor drugs for the treat-
ment of advanced colorectal cancer [2,3]. It contains a
bulky carrier ligand within its structure, and forms DNA
adducts that more effectively inhibit DNA synthesis;
however, these adducts are generally considered to be
more cytotoxic than those of either cisplatin or carbo-
platin [4,5]. Cytotoxic drugs exhibit obvious toxicity on
the human body, affecting neurotoxicity, gastrointestinal
reaction, and cardiotoxicity, etc. [6]; moreover, the non-
selective nature of cytotoxic drugs regarding normal and
pathological tissue poses a challenge for the treatment
of tumors. Conventional chemotherapy is not as effec-
tive in colorectal cancer as it is in other cancers since
the drug does not reach the target site in an effective
concentration [7,8]. Thus, effective treatment demands
an increased dose, which may lead to negative side
effects. If drugs were targeted to the tumor cells, these
limitations would be overcome, and this in turn would
be advantageous for the cancer treatment.
Liposomes are small, spherically shape vesicles that
can be produced from cholesterols, non-toxic surfac-
tants, sphingolipids, glycolipids, long chain fatty acids
and even membrane proteins. Liposomes were among
the first nanomolecular drug delivery systems to demon-
strate the increased delivery of small molecular weight
anticancer drugs to solid tumors by altering the biodis-
tribution of associated drugs [9,10]. It has been pre-
viously reported that liposomes attach to cellular
membranes and appear to fuse with them, thus releasing
their contents into the cells [11]. Alternatively, lipo-
somes are taken up by the cell, their phospholipids are
incorporated into the cell membrane, and the drug
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though, were in the body for only a short duration, and
many were phagocytized by the reticuloendothelial sys-
tem (RES). However, the 1,2-distearoyl-sn-glycero-
3-phosphoethanolamine-N-[maleimide(polyethylene
glycol)-2000] (DSPE-PEG2000) modification to the
surface of a liposome potentially prevents interactions
in-vivo, thus extending the circulation lifetime of the
liposome [13-15]. In tumor tissue, because tumor cells
grow so quickly, newly formed tumor vessels are com-
prised of poorly-aligned and defective endothelial cells
with wide fenestrations that lack a smooth muscle layer
and innervation with the wider lumen. Furthermore,
tumor tissues usually lack effective lymphatic drainage
[16]. Tumor microvessel permeability is 400~600 nm
with permeability for macromolecules having a molecu-
lar weight of 2.5 × 10
4~16 × 10
4 Da [17]. These factors
lead to abnormal molecular and fluid transport
dynamics. Therefore, enhancement of the extravasation
of certain sizes of molecules, such as macromolecular
drugs or liposomes, leads to a much greater accumula-
tion in tumour tissue versus normal tissue. Due to the
tumor selective enhanced permeability and retention
effect (EPR), this results in extensive extravasation of
the liposomes [16,18]. In solid tumours, the EPR effect
is a universal phenomenon in which liposomes are pas-
sively targeted to tumour tissue, ultimately leading to
enhanced accumulation of the liposomes in the tumor
interstitium [19].
Recently, FAD of USA approved a few liposomal pro-
ducts, such as Evacet, AM Bison, and doxorubicin in a
long-circulating PEG-coated liposome. There have been
initial reports indicating that the use of individual func-
tionalities has been demonstrated to be associated with
highly positive clinical outcomes [20-22]. However, there
is currently no commercially available PEG-liposomal
L-oHP product, and studies are still in the experimental
stage. There are few reports published regarding PEG-
liposomal L-oHP treatment of colorectal cancer. Here,
we investigated the therapeutic tumour targeting activity
of PEG-liposomal L-oHP in-vitro in SW480 cells and
in-vivo in a nude mice solid tumour model.
Results
Characteristics of long-circulating liposomes (PEG-
liposomes) and cellular uptake
We selected an increased particle size of PEG-lipo-
somes through a series of filtration steps using a poly-
carbonate membrane filter at a pore size of 100 nm.
P E G - l i p o s o m e sw i t hap a r t i c l es i z eo f1 5 1 . 5 6±1 5 . 5 7
nm and zeta-potential of -23.68 ± 2.35 mv were
obtained, as determined by laser grain size analysis.
The entrapment efficiency of the liposomes was
(42.96 ± 6.45)% as determined by HPLC. These values
are higher than those reported recently by another
group. Flow cytometry demonstrated that after incuba-
tion in medium containing Dio-labeled liposomes for
2 h, the PEG-liposomes conjugated with cells, and
exhibited an enhanced mean fluorescence intensity
upon extended induction time; the mean fluorescence
intensity at 24 h was 3.28-fold greater than the inten-
sity measured at 2 h. The immunofluorescence assay
revealed considerable aggregation of liposomes within
cells at 24 h (Figure 1).
In-vitro drug release and cell viability assay
We used the dialysis method to evaluate L-oHP release
from encapsulated PGE-liposomes in-vitro, and the drug
concentration was then analyzed by HPLC. The cumula-
tive percentage release demonstrated that the amount of
drug released from PEG-liposomes was gradually
increased over time, and after 120 h there was an
increase of over 89%. The free drug exhibited the
highest level (94%) at 2 h, confirming the fact that PEG-
liposomes act as a barrier against diffusion of hydrophi-
lic drugs.
The viability of cells was analyzed by the MTT colori-
metric assay after treatment with empty PEG-liposomes
(2.6 μmol/ml), free L-oHP (28 μg/ml) and PEG-liposomal
L-oHP (containing L-oHP 28 μg/ml), respectively. Cell
viability was decreased with the length of exposure, with
a maximum reduction occurring at 12 h. The empty
PEG-liposomes exhibited significantly less cytotoxicity.
Analysis of apoptosis
Upon exposure of SW480 cells to free L-oHP or PEG-
liposomal L-oHP, cellular apoptosis was assessed by
flow cytometry, which demonstrated that PEG-liposomal
L - o H Pi n d u c e dS W 4 8 0a p o p t o t i ci n c i d e n c eo f( 2 3 . 2 1±
3.38)% (Figure 2A). The gel electrophoretic analysis of
internucleosomal DNA fragmentation demonstrated the
presence of primarily high molecular weight DNA as
seen with the untreated control. A DNA ladder pattern,
the typical feature of apoptosis, was distinctly observed
(Figure 2B).
Figure 1 Cellular uptake of liposomes. The liposomes conjugated
with cells after 2 h, and cellular uptake of liposomes increased over
time. Cells were incubated with PI, which stained nuclei red, and
Dio-labelled liposomes, which were green in colour. A considerable
number of liposomes aggregated within cells at 24 h (× 400).
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Dio-labeled liposomes were intravenously injected via
the tail vein (after injection, all mice survived), and then
visualized in the tumour tissue by an in-vivo imaging
system. After 12 h, 24 h, 48 h, and 72 h, typical repre-
sentative images were captured (Figure 3). The fluores-
cence intensity distribution of tumour tissue in the
animals was indicated by green fluorescence. The fluor-
escence intensity was maintained at a high level for an
extended period of 24 h. However, immediately follow-
ing intravenous injections, little fluorescence was
observed, excluding part of the tail. The fluorescence
was observed through 72 h, indicating that PEG-
liposomes may continue accumulation.
In-vivo antitumor effect of PEG-liposomal L-oHP
Rapid tumour growth was observed in the mouse control
group; however, significant tumor growth suppression
was demonstrated in mice treated with PEG-liposomal
L-oHP (Figure 4A). The tumour suppression was
(26.08 ± 12.43)%, and PEG-liposomal L-oHP demon-
strated the strongest effect on the survival time - all of
the mice treated with PEG-liposomal L-oHP became
long-term survivors (Figure 4B) (p < 0.01). Throughout
the therapeutic experiment, a noticeable cachexia condi-
tion was observed in the control group, and although no
bodyweight loss was observed in any of the treated
groups, weight loss was significant in the control group
(data not show). These results suggest that treatment
with PEG-liposomal L-oHP improves the median survival
time (MST) of tumor-bearing mice without causing
remarkable toxicity.
Bcl-2, Bax mRNA and protein expression in tumour tissue
To elucidate whether the growth inhibitory effect of
PEG-liposomal L-oHP was attributable to the induction
of apoptosis, Bcl-2 and Bax were analyzed by RT-PCR
or Western blot in tumour tissue. On day 15 after treat-
ment, tumours were resected and total RNA and protein
were extracted from the tumour tissue. Our experiments
demonstrated that mRNA expression levels of Bcl-2
were remarkably decreased in the PEG-liposomal L-oHP
group; 0.27-fold compared with free L-oHP, whereas,
Bax mRNA increased 1.32-fold compared with free
L-oHP (Figure 5A). Protein expression tendency of
Bcl-2 and Bax were 0.88-fold and 1.61-fold in compari-
son, respectively (Figure 5B). These results indicated
that apoptosis was strongly induced by PEG-liopsomal
L-oHP.
Discussion
The non-selectivity of cytotoxic drugs between normal
tissue and the pathological site poses a tumor treatment
strategy challenge. To obtain increased therapeutic effi-
cacy, a drug carrier must achieve increased delivery of
Figure 2 Apoptosis of SW480 cells. SW480 cells treated with free
L-oHP (28 μg/ml) or PEG-Liposomal L-oHP (containing L-oHP 28 μg/
ml), PEG-Liposomal L-oHP induced marked apoptosis compared
with free L-oHP (P < 0.01). A, flow cytometery; B, DNA
fragmentation. M: marker (4000 bp). 1: Control. 2: Free L-oHP. 3:
PEG-liposomal L-oHP.
Figure 3 Control mice intravenously injected with Dio-labeled
liposomes at 12 h, 24 h, 48 h, and 72 h. On day 10 after tumor
inoculation mice received an intravenous injection of fluorescently
(Dio) labeled empty PEG-liposomes (no drug) at a dose of 0.5 μmol
lipid/g. At 12, 24, 48, and 72 h post-injection, in-vivo images were
created.
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enhanced interaction of the drug with, and subsequent
internalization by, tumor cells. Liposomes, as carriers of
chemotherapeutic agents, are able to change the distri-
bution of these agents within the body and decrease
their toxicity [23,24]. Therefore, drug-loaded liposomes
offer a new approach for the treatment of colorectal
cancer.
Polyethylene glycol (PEG)-coated liposomes (PEG-
liposomes), are stable and not easy to be taken up by
cells of the reticuloendothelial system (RES), and exhibit
reduced drug leakage compared with conventional lipo-
somes [25]. It has been previously reported that PEG
modification of liposomes increases their affinity to can-
cer cells and increases the cellular uptake of drugs
[26-28]. The toxicity of PEG-liposomes for cells should
be taken into consideration, and some previous reports
have indicated that the toxicity is indeed lower [29,30].
In our experiment, the empty PEG-liposomes in-vitro
exhibited significantly less cytotoxicity for SW480 cells.
The tumour cells took up large numbers of PEG- lipo-
somes, which is in concordance with reports by other
groups [31]. However, PEG-liposomes containing a drug
increase toxicity. Our MTT assays showed that PEG-
liposomal L-oHP (containing L-oHP 28 μg/ml) had sig-
nificantly greater cytotoxic effects than free oxaliplatin
(28 μg/ml). When we assessed their effects on apoptosis,
as determined by flow cytometry and the DNA Ladder
method, we observed that, at an identical dose, PEG-
liposomal L-oHP demonstrated a significantly greater
effect on apoptosis than did free L-oHP. PEG-liposomes
exhibited tumour-targeted delivery in these cells.
Previous studies have demonstrated that PEG-
modified liposomes act primarily through vesicular orga-
nelles, and are preferentially taken up by angiogenic
tumour endothelium [32]. To obtain sufficient antitu-
mor activity with liposomal anticancer drugs, optimiza-
tion of the therapeutic regimen is of great importance.
Figure 4 Tumor growth suppression and survival time.O nd a y
12 after tumour inoculation, mice were treated ith free L-oHP (5
μg/g), PEG-liposomal L-oHP (containing L-oHP 5 μg/g), or 5%
dextrose solution. Antitumor activity as assessed by tumour size and
survival of tumour-bearing mice. A, Relative tumor volume (RTV),
data represent mean ± SD (n = 6). ** P < 0.01 compared with the
other group. B, The percentage increase in life span (ILS%).
Figure 5 The mRNA and protein expression of Bcl-2 and Bax in tumour tissue. On day 15 after treatment, the total mRNA and protein was
extracted from tumour tissue. A, The mRNA expression. Agarose gel electrophoresis result shown in which expression of Bcl-2 is down-regulated
and expression of Bax is up-regulated; B, The protein expression. Cell lysates were separated on 12% SDS-PAGE gels, Bcl-2 was down-regulated,
whereas Bax was up-regulated. Data are expressed as mean ± SD (n = 3). ** P < 0.01 compared with the other group.
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tumour in particular), the permeability of the vascula-
ture is generally increased compared to normal tissues
[32,33]. Therefore, these may provide a channel allowing
liposomes to more easily target tumour tissue. After
receiving intravenous injections of Dio-labeled PEG-
liposomes, mice were able to survive. Experiments pre-
sented in this study indicate that PEG-liposomes effi-
ciently accumulate in tumor tissue (Figure 3), and
maintain a high level over 24 h, which is in concordance
with previous reports from other groups [31,34].
Furthermore, the fluorescence remained detectable even
after 72 h. The plasma clearance of anionic molecules
occurred more slowly than for cationic molecules [35].
Based upon evidence from the in-vitro cell experiments
and the mouse tumour model, a higher concentration
and longer blood residence time of liposomes would
result in greater efficiency of extravasation per unit
volume of convective transport [36,37], and this would
explain the fact that liposomes remain in the tumor
tissue.
Additionally, to investigate the treatment availability of
PEG-liposomal L-oHP, Bcl-2 and Bax were evaluated.
Bcl-2 and Bax are members of the Bcl-2 family, Bax is a
proapoptotic protein that induces mitochondrial outer
membrane permeabilization (MOMP), causing the
release of caspase activating proteins. In contrast, Bcl-2 is
an anti-apoptotic protein and guardian of the outer
membrane and it preserves its integrity by opposing Bax;
they are associated with apoptosis necrosis, and autop-
hagy, and regulate all major types of cell death [38,39].
We used the level of genes and protein to indicate treat-
ment results. After treatment with PEG-liposomal
L-oHP, tumour cell predominance of apoptosis in tumor-
bearing nude mice was induced, and Bcl-2 mRNA and
protein expression were down-regulated, whereas Bax
was up-regulated (Figure 5). This demonstrated that such
liposomal L-oHP formulation exhibits potent in-vivo
antitumor activity, presumably via a dual targeting
approach against both tumour endothelial cells and
tumour cells [40,41].
The PEG-liposomal L-oHP accumulated in the
tumour tissue, following uptake by endothelial cells as
well as tumor cells, and liposomes were then degraded,
while intracellular drug delivery increased the concen-
tration of drug within cells and slowed drug efflux
[42-44]. These findings indicate that liposome encapsu-
lation of chemotherapeutic drugs enhances their
damaging effects on tumour cells. At present, FDA
approved liposomal products (Evacet, doxorubicin lipo-
somes, etc.) have the advantage of high encapsulation
efficiency, rapid release rate, and so forth. As to our
study, further research is needed in order to improve
drug encapsulation efficiency and stability, as well as
further studies involving dynamic research in a clinical
setting.
Conclusion
The experiments presented in this report indicate that
PEG-liposomal L-oHP achieves a better therapeutic
response than the equivalent dose of free L-oHP, and it
indicates the potentially wide application for this type of
drug target for tumors and other tissues, with the
advantage of the ability to overcome some major limita-
tions in conventional anticancer chemotherapy. This
s t u d ym a yp r o v i d et h er a t i o n a l ef o rt h ec l i n i c a la p p l i c a -
tion of CRC. Nevertheless, further studies are warranted
to elucidate the underlying molecular mechanism.
Methods
Animals and tumor cell line
Female BALB/c nude mice, 3 weeks old, were obtained
from Center of Laboratory Animals, Chongqing Medical
University (Permit Number: SCXK(jing) 2009-0004). All
animal experiments were evaluated and approved by the
Animal and Ethics Review Committee. The human
colorectal carcinoma cell line (SW480) was obtained
from the Institute of Life Science of Chongqing Medical
University, and it was maintained in RPMI 1640 (Sigma,
St. Louis, MO) supplemented with 10% fetal bovine
serum (FBS) (HyClone, Logan, UT) in a 5% CO2 incuba-
tor at 37°C.
Preparation of liposomes
PEG-liposomes were prepared using lecithin (Sigama
Co., US), cholesterol (Sigama Co., US), and DSPE-
PEG2000 (Avanti Polar Lipids Inc. US) as previously
described [31]. The molar ratio was 2.0:1.0:0.2. In the
targeting experiments, 2 nmol/ml of the fluorescent
lipid membrane marker, Dio (Vigorous Biotech Co. Ltd.
China), was added to the lipid mixture. The liposomes
were prepared using the reverse-phase evaporation
method. Briefly, lipids (50 mmol) were dissolved in
15 ml of chloroform and then 5 ml of L-oHP solution
(1 mg/ml) in 5% (w/v) dextrose was dropped into the
lipid mixture to form W/O emulsion. For preparation of
no drug-containing liposomes, 5% dextrose solution was
added instead of L-oHP solution. The volume ratio of
the aqueous to the organic phase was maintained at 1:3.
The emulsion was sonicated for 10 min (40 W) and
then the organic phase was removed to form the
liposomes by evaporation in a rotary evaporator at 40°C
under vacuum at 0.045 mPa for 2 h. The resulting
liposomes were extruded through a polycarbonate mem-
brane (Millipore, US. 100 nm pore size).
The grade size and zeta-potential were detected by
Laser Particle Size Analyzer (Zetasizer, Malvern). Using
a transmission electron microscope (Hitachi S-3000N,
Yang et al. BMC Biotechnology 2011, 11:21
http://www.biomedcentral.com/1472-6750/11/21
Page 5 of 8japan), the form feature of PEG-liposomes was deter-
mined. The free L-oHP was removed by ultrafiltration
(MW 100 kDa, 12,000 r/min 20 min). The entrapment
efficiency of the liposomes was determined by high-
performance liquid chromatography (HPLC, SY-8100,
Beijin, China). In-vitro drug release from PEG-liposomes
was studied using a dialysis method as described by
Zhang et al. [45].
Cellular uptake of Dio-labeled PEG-liposomes
SW480 cells were seeded onto 6-well plates in 1 ml of
RPMI 1640 medium containing 10% FBS and pre-
incubated for 24 h. After removal of culture medium,
1 ml of fresh medium containing the Dio-labeled PEG-
liposomes (2 μmol/ml) was added, followed by incubation
a t3 7 ° C .A t0 ,2 ,4 ,8 ,1 2a n d2 4hp o s t - i n c u b a t i o n ,t h e
cells were trypsinized, followed by two washes with cold
phosphate buffered saline (PBS). The cells were re-
suspended in 400 μlo fP B S( 1×1 0
6/ml). The cellular
uptake of Dio-labeled liposomes was quantified using a
flow cytometer (FACS Aria, Becton, Dickinson and Com-
pany), equipped with an argon-ion laser and 488 nm band
pass filters for emission measurements. Approximately
10,000 events were acquired per sample. Cells were also
plated onto glass slides and incubated with Dio-labeled
liposomes, and the cellular uptake of liposomes was deter-
mined by measuring fluorescence.
Cytotoxicity assay
Cytotoxicity of L-oHP formulations was determined by
the 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium
bromide (MTT) assay, as described previously [33].
Briefly, cells in the logarithmic growth phase (5 × 10
3
per well) were placed in wells of a 96-well plate and
incubated for 24 h. The culture medium was replaced
with fresh medium containing various concentrations of
blank liposomes, free oxaliplatin, or PEG-liposomal
L-oHP. After treatment, the culture medium was
removed and the cells were incubated with MTT (final
concentration 10%) for 4 h at 37°C. Then 150 μl DMSO
was added to each well to dissolve formazan crystals.
The absorbance of each well was read at 570 nm on a
microplate reader, and used to determine IC50 values
(IC50 values represent L-oHP concentrations that cause
50% cell death). The concentration of oxalipatin lipo-
somes was expressed as 1/2 the IC50 of the working
concentration of oxaliplatin.
Detection of apoptosis by flow cytometry
SW480 cells cultured in 6-well plates were treated with
free oxaliplatin (28 μg/ml) or PEG-liposomal L-oHP
(containing L-oHP 28 μg/ml) for 12 h, along with a
blank control with no drug treatment. The cells were
trypsinized, followed by two washes with cold PBS,
re-suspended in 400 μlo fP B S( 1×1 0
6/ml), and
incubated in the dark for 15 min following addition of
Annexin V-FITC (5 μl). Cells were subsequently treated
with PI (10 μl) and incubated in the dark for 5 min
prior to detection by flow cytometry. Approximately
10,000 events were acquired per sample.
DNA fragmentation analysis for detecting apoptosis
For DNA fragmentation assay, cells were treated as
described above. Adherent and floating cells were recov-
ered and DNA was isolated and evaluated for fragmen-
tation as described previously [46]. DNA samples were
applied on 1.5% agarose gel containing 1% GoldView™.
The gel was examined and photographed using an ultra-
violet gel documentation system (Bio-Rad, Hercules,
CA, USA).
Targeting of Dio-labeled liposomes in tumor-bearing
nude mice
Female BALB/c nude mice were inoculated subcuta-
neously at the inguen region with SW480 Cells
(2 × 10
7/mouse) in a volume of 200 μl (PBS). On day 15
after tumor inoculation, the tumor volume reached
approximately 100 mm
3. Next, intravenous injections of
Dio-labeled PEG-liposomes (0.5 μmol/g) were per-
f o r m e dv i at h et a i lv e i n .A t1 2h ,2 4h ,4 8h ,a n d7 2h
post-injection, nude mice were anesthetized with isoflur-
ane, and fluorescence imaging was performed using the
In-Vivo Imaging System (Mastro Ex, USA) which has an
affiliated anesthesia device.
Therapeutic efficacy of PEG-liposomal L-oHP in
tumor-bearing nude mice
After successful subcutaneously inoculated tumor trans-
plantation, the nude mice were randomly divided into
three groups. Control (n = 6): Received intravenous
injections of 5% dextrose solution; Free L-oHP (n = 6):
Received intravenous injections of 5 μgL - o H P / g ;
PEG-liposomal L-oHP (n = 6): Received intravenous
injections of PEG-liposomal L-oHP (containing L-oHP
5 μg/g). Treatments occurred once every four days, and
the antitumor activity was evaluated in terms of both
relative tumor volume (RTV) and the percentage of
increased life span (ILS%). Tumor volume was calcu-
lated using the method described by Kim [47] and the
ILS was calculated using the method described by Kvie-
cinski [48]. The median survival time (MST) of each
group was recorded.
Reverse transcription-polymerase chain reaction (RT-PCR)
On day 15 after treatment, the nude mice were sacri-
ficed by deep anesthesia, and the tumours were immedi-
ately placed in liquid nitrogen for further experiments.
Total RNA was extracted using TRIZOL (Takara,
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10 μl of reaction mixture containing 1 μgo ft o t a lR N A ,
25 pmol of oligo-dT primer, 10 nmol of dNTP mixture,
20 units of RNase inhibitor, and 2.5 units of AMV
reverse transcriptase (Takara, Dalian, China) at 37°C for
15 min, 85°C for 5 s. PCR amplification was performed
in 25 μl PCR reaction mixture. PCR amplification was
conducted to detect differences among the samples as
follows: 4 min at 94°C for initial denaturation; 30 cycles ×
30 s at 94°C, 30 s at 59°C, and 30 s at 72°C for Bcl-2, Bax;
30 cycles × 30 s at 94°C, 30 s at 60°C, and 30 s at 72°C
for GAPDH. The following primer pairs were used: Bax
(153 bp): 5’-GAT CGA GCA GGG CGA ATG GG-3’
(ForwardPrimer); 5’-CAC GGC GGC AAT CAT CCT
CT-3’ (ReversePrimer); Bcl-2 (350 bp): 5’-CAG ATG
GCA AAT GAC CAG CAGA-3’ (ForwardPrimer),
5’-TGG CAG GAT AGC AGC ACA GGAT-3’ (Reverse-
Primer); GAPDH (526 bp): 5’-AGG TCG GAG TCA
ACG GAT TTG-3’ (ForwardPrimer), 5’-GTG ATG GCA
TGG ACT GTG GT-3’ (ReversePrimer). For the analysis
of PCR products, 6 μl of each PCR reaction was electro-
phoresed on 1.5% agarose gel containing 1% GoldView™.
Band intensity was analyzed with Image system (NIH,
USA) and GAPDH was used as an internal control to
evaluate the relative expression of Bcl-2 and Bax.
Western blot analysis
For isolation of total protein extract, tumour tissues
were washed with ice-cold PBS and lysed in RIPA lysis
buffer (50 mM Tris with pH 7.4, 150 mM NaCl, 1%
Triton X-100, 1% sodium deoxycholate, 0.1% sodium
dodecyl sulphate, and 0.05 mM EDTA) for 30 min on
ice, and then the cell lysate was centrifuged (12,000
r e v s / m i n ,a t4 ° C )f o r1 0m i n .T h es u p e r n a t a n tw a sc o l -
lected and protein content of the extracted samples was
measured using the Bradford protein assay kit (BestBo-
BeiBo, Beijing, China). All samples were kept at -80°C
for further experiments.
Levels of target proteins including Bcl-2, Bax (Santa
Cruz Biotechnology, Inc. 1:200), and b-actin (Bioscience
Company of America, 1:500) were determined by
Western blot analysis using their respective antibodies.
Briefly, total cell lysate was boiled in 5 × loading buffer
(125 mM Tris-HCl, pH 6.8, 10% SDS, 8% dithiothreitol,
50% glycerol, and 0.5% bromchlorphenol blue) for
10 min. Equal amounts of proteins (50 μg) were sub-
jected to 12% SDS-polyacrylamide gel electrophoresis
and transferred to polyvinylidene fluoride membranes
(PVDF). The membranes were blocked with 5% skim
milk in PBS with 0.1% Tween 20 (PBST) for 1 h, and
incubated with primary antibodies overnight at 4°C.
Antibodies were detected by means of HRP-conjugated
secondary antibody (Bioscience Company of America,
1:2000) for 1 h at room temperature. Immunoreactive
bands were visualized using Immobilon™ Western Che-
miluminescent HRP Substrate (Millipore, USA), and
densitometric analysis was performed using the PDI
Imageware System (Bio-Rad, Hercules, CA, USA).
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